Therefore, FASN inhibitors may contribute to antioncogenesis by suppressing tumor-promoting signaling pathways such as AKT, a pathway that is frequently activated in ovarian serous carcinoma [47]. Here, AKT1 is linked to ovarian serous carcinoma.